By Uzma Zafar
ISLAMABAD: About a month after the federal cabinet announced to allow pharmaceutical companies to increase prices of 94 lifesaving medicines to end their chronic shortage in the market, the Drug Regulatory Authority of Pakistan (DRAP) on Wednesday issued a notification in this regard.
Reportedly, the medicines that would witness price hikes included furosemide injections for emergency use in high blood pressure cases; acetazolamide tablets for glaucoma; hydralazine tablets to lower blood pressure and carbamazepine tablets for epilepsy.
According to an earlier statement issued by the Ministry of Health, the designated maximum retail prices would remain in place until June 30, 2021.
